查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600260

甲狀腺癌藥物市場：按藥物類型、給藥方法、分期、癌症類型、最終用戶分類 - 全球預測 2025-2030

Thyroid Cancer Drugs Market by Drug Type (Chemotherapy Drugs, Hormone Therapy Drugs, Immunotherapy Drugs), Mode of Administration (Injectable Drugs, Intravenous Drugs, Oral Drugs), Stage of Disease, Cancer Type, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年甲狀腺癌治療市場價值為8.0601億美元，預計到2024年將達到8.9096億美元，複合年成長率為11.02%，到2030年將達到16.7577億美元。

甲狀腺癌藥物市場範圍包括專門用於治療甲狀腺癌的藥物，例如小分子抑制劑、免疫療法、放射性碘療法和甲狀腺荷爾蒙療法。該領域對於解決未滿足的醫療需求至關重要，因為甲狀腺癌發病率的增加強調了對有效治療方法的需求。這些藥物主要由醫療專業人員在臨床環境中應用，以治療和治療各種類型的甲狀腺癌，包括乳頭狀癌、濾泡狀癌、髓樣癌和未分化癌。最終用途包括醫院、腫瘤中心和專門的癌症治療診所。該市場的關鍵成長要素包括精準醫學和標靶治療的進步、研發投資的增加以及患者對有效治療方案的認知和需求的提高。生物相似藥的出現以及人工智慧在藥物發現中的整合是一個潛在的機會，可以為更個人化的醫療和具有成本效益的治療鋪平道路。為了利用這些機會，製藥公司必須投資強力的研發計劃和策略夥伴關係關係，以加速藥物開發並簡化監管核准。然而，該市場面臨高昂的開發成本、嚴格的法律規範以及與甲狀腺癌治療相關的潛在副作用等限制。此外，與手術治療方法的競爭也是一個問題，因為一些患者選擇手術而不是藥物。在技​​術創新方面，開發新分子標靶、改進給藥系統、探索聯合治療等領域是業務成長的重大機會。市場充滿活力，但受到高度競爭和監管障礙的限制，需要策略規劃和持續創新才能保持競爭力並在全球市場上立足。

主要市場統計
基準年[2023] 80601萬美元
預測年份 [2024] 89096萬美元
預測年份 [2030] 16.7577 億美元
複合年成長率（%） 11.02%

市場動態：揭示快速發展的甲狀腺癌藥物市場的關鍵市場洞察

供需的動態交互作用正在改變甲狀腺癌藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球甲狀腺癌盛行率不斷上升
    • 越來越重視早期診斷和治療
    • 私人組織增加癌症篩檢項目
  • 市場限制因素
    • 與甲狀腺癌治療相關的副作用
  • 市場機會
    • 政府為提高癌症意識和採用報銷政策所做的積極努力
    • 擴大個人化醫療和標靶治療的潛力
  • 市場挑戰
    • 嚴格的政府藥品核准程序

波特五力：駕馭甲狀腺癌藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對甲狀腺癌藥物市場的影響

外部宏觀環境因素在塑造甲狀腺癌治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解甲狀腺癌治療藥物市場的競爭狀況

對甲狀腺癌治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

甲狀腺癌治療市場中的 FPNV 定位矩陣供應商績效評估

FPNV定位矩陣是評估甲狀腺癌藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了甲狀腺癌治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對甲狀腺癌治療藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球甲狀腺癌發生率增加
      • 注重早期診斷、早期治療
      • 私人組織的增加增加了癌症篩檢計劃
    • 抑制因素
      • 與甲狀腺癌治療相關的副作用
    • 機會
      • 政府採取有利措施提高癌症意識並推出保險報銷政策
      • 個人化醫療和標靶治療的指數級潛力
    • 任務
      • 嚴格的政府藥品核准程序
  • 市場區隔分析
    • 藥物類型：快速採用標靶治療，透過減少副作用與改善患者預後直接相關
    • 最終用戶：先進設備促進了各醫院甲狀腺癌藥物的獲取
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類型分類的甲狀腺癌治療市場

  • 化療藥物
  • 荷爾蒙療法藥物
  • 免疫治療藥物
  • 標靶治療

第7章 依管理方式分類的甲狀腺癌治療藥物市場

  • 注射藥物
  • 靜脈注射藥物
  • 口腔醫學

第8章依疾病分期分類的甲狀腺癌治療藥物市場

  • 晚期甲狀腺癌
  • 甲狀腺癌的早期階段

第9章按癌症類型分類的甲狀腺癌治療藥物市場

  • 未分化甲狀腺癌
  • 濾泡性甲狀腺癌
  • 甲狀腺髓樣癌
  • 甲狀腺乳突癌

第10章甲狀腺癌治療市場：依最終用戶分類

  • 醫院
  • 腫瘤門診
  • 調查機構

第11章 美洲甲狀腺癌藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太甲狀腺癌藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲甲狀腺癌藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准selpercatinib 用於治療患有 RET 突變甲狀腺癌的年輕患者，擴大了治療選擇
    • 工業宣佈在甲狀腺癌治療上取得可喜進展
    • Rigel Pharmaceuticals 獲得 Gavreto 在美國的權利，擴大甲狀腺癌的治療選擇
  • 戰略分析和建議

公司名單

  • Abbott Ltd.
  • Aprazer Healthcare Pvt Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • Biovista Inc.
  • Bristol Myers Squibb
  • Dr Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis Inc.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Healthcare Limited
  • Loxo Oncology Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • MSN Laboratories
  • Mylan NV
  • Natco Pharma Ltd.
  • Novartis AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vascular Biogenics Ltd.
Product Code: MRR-434CCDA052BE

The Thyroid Cancer Drugs Market was valued at USD 806.01 million in 2023, expected to reach USD 890.96 million in 2024, and is projected to grow at a CAGR of 11.02%, to USD 1,675.77 million by 2030.

The scope of the thyroid cancer drugs market involves pharmaceuticals specifically designed to treat thyroid cancer, including small molecule inhibitors, immunotherapies, radioactive iodine treatment, and thyroid hormone therapy. This sector is crucial for addressing unmet medical needs, as the rising incidence of thyroid cancer emphasizes the necessity for effective treatments. These drugs are applied primarily in clinical settings by healthcare professionals aiming to manage or cure different types of thyroid cancers such as papillary, follicular, medullary, and anaplastic. The end-use scope includes hospitals, oncology centers, and specialized clinics dedicated to cancer treatment. Key growth influencers in this market include advancements in precision medicine and targeted therapies, increasing R&D investments, as well as rising patient awareness and demand for effective treatment options. The emergence of biosimilars and the integration of AI in drug discovery represent potential opportunities, paving the way for more personalized medicine and cost-effective treatments. To capitalize on these opportunities, pharmaceutical companies should invest in robust R&D programs and strategic partnerships to accelerate drug development and streamline regulatory approvals. However, the market faces limitations such as high development costs, stringent regulatory frameworks, and potential side effects associated with thyroid cancer therapies. Additionally, competition from surgical treatment options poses challenges, as some patients opt for surgery over drug-based therapies. In terms of innovation, areas such as the development of novel molecular targets, improvements in drug delivery systems, and the exploration of combination therapies represent significant opportunities for business growth. The market is dynamic but constrained by high competition and regulatory hurdles, which necessitate strategic planning and continuous innovation to maintain competitiveness and secure a foothold in the global market.

KEY MARKET STATISTICS
Base Year [2023] USD 806.01 million
Estimated Year [2024] USD 890.96 million
Forecast Year [2030] USD 1,675.77 million
CAGR (%) 11.02%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Thyroid Cancer Drugs Market

The Thyroid Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of thyroid cancer cases across the globe
    • Increasing focus on early diagnosis and treatment
    • Rising private organizations increasing cancer screening programs
  • Market Restraints
    • Adverse side effects associated with thyroid cancer treatments
  • Market Opportunities
    • Favorable government initiatives promoting cancer awareness and introduction of reimbursement policies
    • Exponential potential for personalized medicine and targeted therapies
  • Market Challenges
    • Stringent government drug approval procedures

Porter's Five Forces: A Strategic Tool for Navigating the Thyroid Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Thyroid Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Thyroid Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Thyroid Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Thyroid Cancer Drugs Market

A detailed market share analysis in the Thyroid Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Thyroid Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Thyroid Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Thyroid Cancer Drugs Market

A strategic analysis of the Thyroid Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Thyroid Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Ltd., Aprazer Healthcare Pvt Ltd., AstraZeneca PLC, Bayer AG, Biovista Inc., Bristol Myers Squibb, Dr Reddy's Laboratories Ltd., Eisai Co., Ltd., Eli Lilly and Company, Exelixis Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Hetero Healthcare Limited, Loxo Oncology Inc., Lupin Limited, Merck & Co., Inc., MSN Laboratories, Mylan N.V., Natco Pharma Ltd., Novartis AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vascular Biogenics Ltd..

Market Segmentation & Coverage

This research report categorizes the Thyroid Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Chemotherapy Drugs, Hormone Therapy Drugs, Immunotherapy Drugs, and Targeted Therapy Drugs.
  • Based on Mode of Administration, market is studied across Injectable Drugs, Intravenous Drugs, and Oral Drugs.
  • Based on Stage of Disease, market is studied across Advanced-stage Thyroid Cancer and Early-stage Thyroid Cancer.
  • Based on Cancer Type, market is studied across Anaplastic Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer, and Papillary Thyroid Cancer.
  • Based on End User, market is studied across Hospitals, Oncology Clinics, and Research Organizations.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of thyroid cancer cases across the globe
      • 5.1.1.2. Increasing focus on early diagnosis and treatment
      • 5.1.1.3. Rising private organizations increasing cancer screening programs
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse side effects associated with thyroid cancer treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable government initiatives promoting cancer awareness and introduction of reimbursement policies
      • 5.1.3.2. Exponential potential for personalized medicine and targeted therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government drug approval procedures
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Proliferating adoption of the targeted therapy drugs directly translating to better patient outcomes with fewer adverse effects
    • 5.2.2. End User: Evolving utilization of thyroid cancer drugs across the hospitals owing to the advanced facilities
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Thyroid Cancer Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Chemotherapy Drugs
  • 6.3. Hormone Therapy Drugs
  • 6.4. Immunotherapy Drugs
  • 6.5. Targeted Therapy Drugs

7. Thyroid Cancer Drugs Market, by Mode of Administration

  • 7.1. Introduction
  • 7.2. Injectable Drugs
  • 7.3. Intravenous Drugs
  • 7.4. Oral Drugs

8. Thyroid Cancer Drugs Market, by Stage of Disease

  • 8.1. Introduction
  • 8.2. Advanced-stage Thyroid Cancer
  • 8.3. Early-stage Thyroid Cancer

9. Thyroid Cancer Drugs Market, by Cancer Type

  • 9.1. Introduction
  • 9.2. Anaplastic Thyroid Cancer
  • 9.3. Follicular Thyroid Cancer
  • 9.4. Medullary Thyroid Cancer
  • 9.5. Papillary Thyroid Cancer

10. Thyroid Cancer Drugs Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals
  • 10.3. Oncology Clinics
  • 10.4. Research Organizations

11. Americas Thyroid Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Thyroid Cancer Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Thyroid Cancer Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. FDA Approves Selpercatinib for Young Patients with RET-Altered Thyroid Cancer, Expanding Treatment Option
    • 14.3.2. ONO Pharmaceutical Unveils Promising Advances in Thyroid Cancer Treatment
    • 14.3.3. Rigel Pharmaceuticals Secures U.S. Rights to Gavreto, Enhancing Options for Thyroid Cancer Treatment
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Ltd.
  • 2. Aprazer Healthcare Pvt Ltd.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Biovista Inc.
  • 6. Bristol Myers Squibb
  • 7. Dr Reddy's Laboratories Ltd.
  • 8. Eisai Co., Ltd.
  • 9. Eli Lilly and Company
  • 10. Exelixis Inc.
  • 11. GlaxoSmithKline PLC
  • 12. Glenmark Pharmaceuticals Ltd.
  • 13. Hetero Healthcare Limited
  • 14. Loxo Oncology Inc.
  • 15. Lupin Limited
  • 16. Merck & Co., Inc.
  • 17. MSN Laboratories
  • 18. Mylan N.V.
  • 19. Natco Pharma Ltd.
  • 20. Novartis AG
  • 21. Sanofi S.A.
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. Teva Pharmaceutical Industries Ltd.
  • 24. Vascular Biogenics Ltd.

LIST OF FIGURES

  • FIGURE 1. THYROID CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. THYROID CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. THYROID CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. THYROID CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. THYROID CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INTRAVENOUS DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ADVANCED-STAGE THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY EARLY-STAGE THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES THYROID CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. THYROID CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023